NTLA

Intellia Therapeutics, Inc.

Halal Rating :
Comfortable
Last Price $9.50 Last updated:
Market Cap $2.28b
7D Change -5.47%
1 Year Change -63.64%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • In Vitro
  • In Vivo Diagnostic Substances
Exchange NASDAQ
Next Earnings Date Nov. 11, 2024

Intellia Therapeutics, Inc. is a leading biotechnology company focused on developing curative genome editing treatments using CRISPR/Cas9 technology. The company aims to develop therapeutics for genetic diseases, cancers, and autoimmune conditions. They are pioneering in vivo and ex vivo cell therapies and have multiple candidates in clinical trials.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $9.11m $153.88m - - 0.00% 0.00%
June 30, 2024 $6.96m $146.0m - - 0.00% 0.00%
March 31, 2024 $28.93m $142.94m - - 0.00% 0.00%

Company Impact

Help us evaluate Intellia Therapeutics, Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates